



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,368	04/20/2006	Frederick R. Kettinger	525.1089-PCT-US	5602
20311	7590	08/03/2007	EXAMINER	
LUCAS & MERCANTI, LLP 475 PARK AVENUE SOUTH 15TH FLOOR NEW YORK, NY 10016			VO, TUYEN KIM	
ART UNIT		PAPER NUMBER		
2876				
MAIL DATE		DELIVERY MODE		
08/03/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/560,368	KETTINGER ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Tuyen Kim Vo	2876	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_\_.
- 2a) This action is FINAL.                            2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-24 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 09 December 2005 is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date: _____
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>12/09/2005</u>	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____

**DETAILED ACTION**

***Claim Objections***

1. Claims 10 and 23 are objected to because of the following informalities:  
Re claim 10, the recitation of "HPLC" is suggested to change to -- High Performance Liquid Chromatograph --.  
Re claim 23, the recitation of "the film" in line 2 is suggested to change to --a film --.  
Appropriate corrections are required.

***Claim Rejections - 35 USC § 112***

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:  
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
3. Claim 9 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
4. Claim 9 recites the limitation "said covert marking" in 1. There is insufficient antecedent basis for this limitation in the claim.

***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

6. Claims 1, 3, 4, 6-8, 11-18, 20 and 21 are rejected under 35 U.S.C. 102(e) as being anticipated by Nellhaus et al. (Nellhaus) (US 6,543,692 B1, cited by the applicant).

Re claims 1, 14 and 17, Nellhaus, as shown in figure 10, teaches a solid form drug (72) comprising a core portion (75) having sufficiently low friability to receive a printed or etched marking on a surface thereof; a readable printed or etched marking (data matrix 82) on the surface of the core, the marking providing identification/authentication of the oral dosage form. See column 4, lines 26-50.

Re claim 3, Nellhaus further teaches the printed or etched marking is a barcode (data matrix 82). See column 4, lines 51-54.

Re claim 4, Nellhaus further teaches the barcode is a 2D data matrix barcode. See column 1, lines 13-18.

Re claim 6, Nellhaus further teaches the marking is readable with a barcode scanner (a pen, figure 13). See column 5, line 66 to column 6, line 2.

Re claim 7, Nellhaus further teaches the marking is readable with detection equipment which does not depend upon visible light waves. See column 2, lines 29-35 and column 3, lines 15-19.

Re claims 8 and 20, Nellhaus further teaches a covert marking thereon (hybrid data matrix symbol 90, figure 12). See column 5, lines 49-57.

Re claims 11 and 18, Nellhaus further teaches the surface of the core further comprises a debossed region (icon 75, figure 10, which serves as a debossed region) into which the printed or etched marking is place. See column 4, lines 44-47.

Re claim 12, Nellhaus further teaches the debossed region has a substantially horizontal plane with respect to the center of the core. See figure 10; column 4, line 44-47.

Re claims 13, 15, 16 and 21, Nellhaus further teaches the core has an ink coating applied to a portion thereof to the marking being applied thereto. See column 3, lines 10-22.

***Claim Rejections - 35 USC § 103***

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

8. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 2, 5, 19, 23 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nellhaus et al. in view of Sullivan et al. (Sullivan) (US 5,992,742 cited by the applicant).

Re claims 2 and 19, Nellhaus teaches all subject matter claimed (see section 3) except for the core is film coated prior to the printed or etches marking being applied thereto.

Sullivan, in the same field of endeavor, teaches a barcode is printed on a label of a pill, which has a code-receiving layer (a core portion) that has a film (a protein based film) coated prior to the printed being applied thereto. See column 11, lines 36-42.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the invention of Nellhaus to employ the film coated on the core portion as taught by Sullivan so that to easily adhere to the pill which marking can be easily applied thereon. See column 11, lines 36-55 of Sullivan.

Re claim 5, Sullivan further teaches the film coat contains a colorant (the gelatin film has slightly yellow color, see Webster's II, new college dictionary, Houghton Mifflin Company, Boston, New York, Copyright © 1995, page 464). See column 11, lines 36-38.

Re claims 23 and 24, Nellhaus teaches all subject matter claimed except for the film coating. Nellhaus also teaches the different sizes (concentrating) of the marking such as 4x4, 5x5,..etc.., see column 1, lines 25-62. Therefore, to provide the marking

with the range of about 2 to about 5 ppm is obvious from the different sizes of Nellhaus since it is just a variation of sizing.

Sullivan teaches a film (a protein based film such as keratin or gelatin film) coating on the code-receiving layer. See column 11, lines 36-42.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the invention of Nellhaus to employ the film coated on the core portion (code-receiving layer) as taught by Sullivan so that to easily adhere to the pill which marking can be easily applied thereon. See column 11, lines 36-55 of Sullivan.

10. Claims 9 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nellhaus et al. in view of Johnson et al. (Johnson) (US 6,171,618 B1).

Re claim 9, Nellhaus teaches all subject matter claimed (see section 3) except for the covert marking (hybrid data matrix symbol 90, figure 12) is detectable by aroma or taste.

Johnson teaches a taste masking layer can be added to a tablet. See column 12, lines 65-67; column 15, lines 57-61.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the invention of Nellhaus by providing the taste masking layer as taught by Johnson to the cover marking of Nellhau in order to reduce/eliminate the bitter taste of the medicine/pill when the patient places the medicine/pill in his/her mouth. Such modification would further encourage the children/minors of taking the flavored medicine/pill when needed.

Re claim 10, Nellhaus teaches all subject matter claimed (see section 3) except for the covert marking (hybrid data matrix symbol 90, figure 12) is detectable using HPLC.

Johnson teaches a HPLC system uses to monitor or detect the dosage.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the covert marking of Nellhaus so that it can be detected by HPLC as taught by Johnson since HPLC is used to monitor or detect the chemical using UV detecting and such modification of the covert marking of Nellhaus would not involve any inventive feature.

11. Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over Nellhaus et al. in view of Krubert (US 4,578,273).

Re claim 22, Nellhaus teaches all subject matter claimed (see section 3) except for the pad printing is applied using an Opacode ink.

Krubert teaches a pad printing is applied using an opacode ink. See column 6, lines 7-13.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the invention of Nellhaus by using the opacode ink as taught by Krubert since Opacode ink is FD&C approved and it may be easily and rapidly printed without runs, smearing or blotting on the product. See column 1, lines 49-58 of Krubert.

**Conclusion**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tuyen Kim Vo whose telephone number is 571-270-1657. The examiner can normally be reached on Monday - Friday, 7:30a.m. - 5:00p.m., EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Lee can be reached on 571-272-2398. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

*tkv*  
Tuyen Kim Vo  
Patent Examiner  
Art Unit 2876  
July 23, 2007.

  
MICHAEL G. LEE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 2800